Overview

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Alprazolam (Xanax) will blunt the body's ability to defend itself from low blood sugar.
Phase:
N/A
Details
Lead Sponsor:
Vanderbilt University
Vanderbilt University Medical Center
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Alprazolam